Laron Zvi
Endocrinology and Diabetes Research Unit, Schneider Children's Medical Center, WHO Collaborating Center for the Study of Diabetes in Youth, Tel Aviv University, Tel Aviv, Israel.
Pediatr Endocrinol Rev. 2004 Nov;2 Suppl 1:78-85.
Insulin-like growth factor I (IGF-I) is a peptide synthesized mainly in the liver by stimulation by pituitary growth hormone (GH). It circulates almost entirely bound to its binding proteins. It is the anabolic effector hormone of GH. It is the only treatment in states of GH resistance such as Laron syndrome and blocking antibodies to human GH. As it suppresses insulin and GH secretion it has been used in states of insulin resistance including Type II diabetes mellitus. IGF-I is administered by once or twice daily injections. Adverse effects are mostly caused by overdosage. The usual daily dose in children ranges from 100-200 microg/kg.
胰岛素样生长因子I（IGF-I）是一种主要由垂体生长激素（GH）刺激肝脏合成的肽。它几乎完全以与结合蛋白结合的形式循环。它是GH的合成代谢效应激素。它是治疗诸如拉伦综合征和人GH阻断抗体等GH抵抗状态的唯一药物。由于它能抑制胰岛素和GH分泌，已被用于包括II型糖尿病在内的胰岛素抵抗状态。IGF-I通过每日注射一次或两次给药。不良反应大多由过量用药引起。儿童的通常日剂量为100 - 200微克/千克。
